首页> 外文期刊>The annals of pharmacotherapy >Proton pump inhibitor use and association with spontaneous bacterial peritonitis in patients with cirrhosis and ascites [L'utilisation des inhibiteurs de la pompe à protons chez les patients cirrhotiques présentant une ascite]
【24h】

Proton pump inhibitor use and association with spontaneous bacterial peritonitis in patients with cirrhosis and ascites [L'utilisation des inhibiteurs de la pompe à protons chez les patients cirrhotiques présentant une ascite]

机译:质子泵抑制剂在肝硬化和腹水患者中的使用以及与自发性细菌性腹膜炎的关系

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: To evaluate the literature regarding the efficacy and safety of proton pump inhibitors (PPIs) when they are used in patients with cirrhosis and ascites. DATA SOURCES: A literature search was conducted using MEDLINE (1966-May 2012) and Web of Science (1990-May 2012) with the terms proton pump inhi-bitor, antisecretory therapy, cirrhosis, ascites, spontaneous bacterial peritonitis, and Clostridium difficile. The search was restricted to articles published in English on the use of PPIs in humans. Reference citations from identified published articles were reviewed for relevant information. STUDY SELECTION AND DATA EXTRACTION: All articles in English identified from the data sources were evaluated for inclusion. One case series, 8 retrospective case-control trials, and 1 meta-analysis were identified. DATA SYNTHESIS: Cirrhosis may cause complications such as portal hyper-tension, esophageal varices, and ascites. Patients may be prescribed PPIs without clear indications or because of their propensity to develop upper gastro-intestinal symptoms and bleeding. However, gastric acidity is a major nonspecific defense mechanism and there is insufficient evidence on the need for chronic acid suppression in patients with cirrhosis. It is postulated that the portal hypertensive environment in cirrhosis and the acid suppression from PPIs can increase the risk of spontaneous bacterial peritonitis and C. difficile infection in patients with cirrhosis with ascites. Several retrospective studies and 1 meta-analysis have confirmed this association. CONCLUSIONS: Patients with cirrhosis and ascites should be monitored carefully while on PPIs for a possible increased risk of infection from spontaneous bacterial peritonitis and C. difficile. Prospective randomized trials are needed to confirm this association. Clinicians should be aware of this lesser known adverse effect of PPIs.
机译:目的:评估有关质子泵抑制剂(PPI)在肝硬化和腹水患者中使用时的功效和安全性的文献。数据来源:文献检索使用MEDLINE(1966年-2012年5月)和Web of Science(1990年-2012年5月),涉及质子泵抑制剂,抗分泌疗法,肝硬化,腹水,自发性细菌性腹膜炎和艰难梭菌。该搜索仅限于以英文发表的有关在人体内使用PPI的文章。审查了已发表文章的参考文献,以获取相关信息。研究选择和数据提取:对所有从数据源中识别出的英文文章进行评估以纳入。确定了一个病例系列,8项回顾性病例对照试验和1项荟萃分析。数据综合:肝硬化可能引起并发症,例如门脉高压,食管静脉曲张和腹水。可能会给患者开具PPI,而没有明确的适应症或由于他们倾向于发展上消化道症状和出血。然而,胃酸度是主要的非特异性防御​​机制,尚无足够证据表明肝硬化患者需要长期抑制酸。据推测,肝硬化腹水的门脉高压环境和PPI抑制酸可增加自发性细菌性腹膜炎和艰难梭菌感染的风险。若干回顾性研究和1项荟萃分析已证实这种关联。结论:肝硬化和腹水患者在服用PPI时应仔细监测,以防自发性细菌性腹膜炎和艰难梭菌感染的风险增加。需要前瞻性随机试验以确认这种关联。临床医生应意识到这种鲜为人知的PPI不良反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号